Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
11
×
national blog main
life sciences
national top stories
biotech
boston
san francisco blog main
deals
startups
san francisco top stories
san diego blog main
vc
healthcare
medical devices
new york blog main
san diego top stories
seattle blog main
software
fda
investing
new york top stories
san francisco
venture capital
clinical trials
dna
healthtech
medicare
raleigh-durham blog main
roboticsai
roche
seattle top stories
tech
accelerator
acetylon pharmaceuticals
agios therapeutics
airbnb
amazon
amazon web services (aws)
ambys medicines
What
startup
11
×
million
therapeutics
healthcare
adding
approach
big
biotech
boston
called
deal
developing
device
make
medical
medicines
new
patients
sciences
acquire
acquisition
admits
ago
aiming
aims
amazon’s
ambys
analytics
andreessen
answer
atrial
based
beam
beta
bets
biofourmis
bionics
biotechs
blood
boost
Language
unset
Current search:
startup
×
" boston top stories "
×
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
Censinet Takes Off With $7.8M to Track Cyber Risks in Healthcare
@xconomy.com
5 years ago
Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests
@xconomy.com
5 years ago
To Boost Cancer Pipeline, Gilead Bets at Least $50M on Startup Tango
@xconomy.com
5 years ago
Andreessen Leads $300M Bet on Devoted Health’s Senior Care Approach
@xconomy.com
5 years ago
Circulation CEO Talks Sale to LogistiCare & Amazon’s Healthcare Play
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
Boston Scientific Continues M&A Streak with $202M Deal for Cryterion
@xconomy.com
6 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M